key: cord-0795645-y9o3ofqc
authors: Reis, Thiago; Ostermann, Marlies; Zarbock, Alexander; Kellum, John A; Ronco, Claudio
title: Dapagliflozin in patients with COVID-19: mind the kidneys
date: 2021-12-15
journal: Lancet Diabetes Endocrinol
DOI: 10.1016/s2213-8587(21)00329-6
sha: f1bbd4dcc9bd3747a538c06d6cd3944ee70bea57
doc_id: 795645
cord_uid: y9o3ofqc

nan

Adding dapagliflozin 10 mg versus placebo to usual care did not affect the two primary outcomes: reduction in organ dysfunction or death and improvement in clinical recovery. Development of acute kidney injury was hierarchically the most important secondary outcome. The authors concluded that dapagliflozin did not increase the risk of acute kidney injury because there was no difference in the proportion of patients with serum creatinine concentrations two times that reported at baseline. However, doubling of serum creatinine represents acute kidney injury stage 2 according to current Kidney Disease: Improving Global Outcomes (KDIGO) criteria 2 and does not exclude stage 1 acute kidney injury or worse stages that manifest only as oliguria. A retrospective cohort study of patients hospitalised with COVID-19 confirmed that acute kidney injury occurred in 1835 (46%) of 3993 individuals. 3 Morality was significantly worse in those with acute kidney injury. Of note, 716 (39%) of 1835 patients with acute kidney injury cohort in the retrospective study would not have met the acute kidney injury criteria used in DARE-19 and would have been missed. In DARE-19, acute kidney injury occurred in only 62 (5%) of 1250 patients, but the true incidence of was likely much higher.

Dapagliflozin is a SGLT2 inhibitor associated with a haemodynamically driven reduction in eGFR. 4 Patients hospitalised with COVID-19 are at high risk of developing kidney injury for various reasons, such as dehydration and hypotension (70%), and viral sepsis (22%). 3, 5 In this context, starting a drug that might reduce glomerular perfusion could have a detrimental effect. In our opinion, it is premature to claim that dapagliflozin is safe with respect to kidney function in patients who are acutely ill. To avoid potentially misleading conclusions and to prevent iatrogenic acute kidney injury in high risk patients, we strongly recommend that appropriate criteria are applied in future clinical trials. Furthermore, studying the effect of dapagliflozin using biomarkers of glomerular and tubular injury would add granularity to the functional criteria (serum creatinine elevation or urine output decline). 6 We strongly suggest that full KDIGO criteria be used (possibly with the inclusion of biomarkers of kidney damage) in upcoming investigations. 

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Acute kidney injury

AKI in hospitalized patients with COVID-19

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Acute kidney injury in 3182 patients admitted with COVID-19: a single-center, retrospective, case-control study

Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement